Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor.
about
The C-kit receptor-mediated signal transduction and tumor-related diseasesCharacterization and Targeting of Platelet-Derived Growth Factor Receptor alpha (PDGFRA) in Inflammatory Breast Cancer (IBC)Allosteric communication across the native and mutated KIT receptor tyrosine kinase.Autophagy is involved in endogenous and NVP-AUY922-induced KIT degradation in gastrointestinal stromal tumors.Synchronous occurrence of gastrointestinal stromal tumor and acute myeloid leukemia: A case report and review of the literature.Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trialExpression and clinicopathological significance of CD9 in gastrointestinal stromal tumor.Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis.What can molecular pathology contribute to the management of renal cell carcinoma?Molecular mechanisms of drug resistance in tyrosine kinases cAbl and cKit.Clinical relevance of pharmacogenetics in gastrointestinal stromal tumor treatment in the era of personalized therapy.Clinical efficacy of second-generation tyrosine kinase inhibitors in imatinib-resistant gastrointestinal stromal tumors: a meta-analysis of recent clinical trials.Gastrointestinal stromal tumor of the adrenal gland:a case report and review of the literature.Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure.Chronic myeloid leukemia: advances in understanding disease biology and mechanisms of resistance to tyrosine kinase inhibitors.Pharmacological cyclin dependent kinase inhibitors: Implications for colorectal cancer.Secondary c-Kit mutations confer acquired resistance to RTK inhibitors in c-Kit mutant melanoma cells.Promoter methylation status of VEGF receptor genes: a possible epigenetic biomarker to anticipate the efficacy of intracellular-acting VEGF-targeted drugs in cancer cells.Why tyrosine kinase inhibitor resistance is common in advanced gastrointestinal stromal tumors.Cross-drug resistance to sunitinib induced by doxorubicin in endothelial cells.Spectrum of mutations in gastrointestinal stromal tumor patients - a population-based study from Slovakia.Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumor after failure with imatinib and sunitinib treatment: A meta-analysis.Establishment and characterization of patient-derived xenograft models of gastrointestinal stromal tumor resistant to standard tyrosine kinase inhibitors.MiR-320a downregulation is associated with imatinib resistance in gastrointestinal stromal tumors.Gastrointestinal stromal tumors (GISTs) express somatostatin receptors and bind radiolabeled somatostatin analogs.[Translational research and diagnosis in GIST].Association of ABCG2 polymorphism with clinical efficacy of imatinib in patients with gastrointestinal stromal tumor.
P2860
Q30419298-E54F27A5-F691-4480-90BF-536C129308B9Q33796945-F4F1A6B6-35A8-4C6D-A9DE-65C104E5984BQ34395251-BE2AB8EA-4E0E-4F16-A9C5-FF7FF47C76EBQ36556257-117D24BF-3268-4888-91CA-592D45743338Q36825019-549300F1-B705-4FFF-A1E4-8B1EA7DC78C5Q36910431-7C0D54A8-6DF5-4CA4-B123-C64EBD833FC8Q37220453-5B1B4230-94B5-4C49-8D7A-8A47F5093DD3Q37688382-744EE9A5-9E4C-4DA1-A9FD-DA40BD949684Q37864528-ADC518B5-5CD2-4EE4-B50B-4AE2EBFDEC03Q37871600-41D4C2DA-2A70-414E-9251-5D863B0C2CBEQ38112821-1079D76A-6093-4C96-830E-BE1FC14550F7Q38266025-25AD05E3-F4FC-42C6-B5FA-958AD763FA8EQ38289207-F5B50C7E-7840-4820-8A68-FDB7A465C47AQ38355156-B098C708-430F-4B66-B4C8-EC65640F4B61Q38363058-0349C8F3-9C9D-4AFF-9C16-95E13735ED08Q38743546-804DFD7D-E0DB-418B-80C0-EED6E2E3F897Q39167351-324021B9-5B58-4BDE-89AF-28859C79528DQ39384319-B99956BB-A960-4B59-906C-CBEDE1A19712Q41873739-B89FE992-2849-4A5E-8A3D-CDC80B88374BQ41921173-E72B4B64-3E43-4FA6-8B2F-E96F012BF0A5Q45205377-97AF62E5-D98D-4CEA-9FCD-0304A8B93D8CQ47105124-CF2A48F9-1BF5-432A-B11F-D1516F80A957Q47140976-538B1FF5-B518-4A36-8521-736F803E562CQ50469164-52CE368B-E646-45F7-AF58-BCB7097059B3Q54473967-C242063B-087C-4A06-A512-6AF000971236Q54484634-2E7B3AF3-3184-43D8-B9FD-00F9ACDDFEEDQ55070104-91F10DB1-130F-4964-889C-EB1213A42C27
P2860
Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 24 December 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor.
@en
Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor.
@nl
type
label
Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor.
@en
Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor.
@nl
prefLabel
Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor.
@en
Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor.
@nl
P2093
P2860
P1476
Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor
@en
P2093
David Reynoso
Jonathan C Trent
Laura Nolden
Suzanne George
Wei-Lien Wang
P2860
P2888
P304
P356
10.1007/S00280-010-1513-8
P478
67 Suppl 1
P577
2010-12-24T00:00:00Z